UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

Rhea-AI Summary

UroGen (Nasdaq: URGN) received FDA clearance of its Investigational New Drug (IND) application for UGN-501, an investigational next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC).

The clearance enables a planned Phase 1 study of intravesical UGN-501, with patient enrollment expected to start in Q4 2026.

Positive

• FDA cleared IND for UGN-501 in non-muscle invasive bladder cancer
• Phase 1 intravesical UGN-501 trial planned to start enrollment in Q4 2026
• Investigational oncolytic virus aims to combine tumor destruction and immune activation
• Targets significant unmet need where NMIBC recurrence rates remain substantial

Negative

• UGN-501 remains at Phase 1 stage with safety and feasibility still unproven
• No clinical efficacy data for UGN-501 in NMIBC reported yet

News Market Reaction – URGN

+0.74%

7 alerts

+0.74% Session close to close

$1.84B Market Cap

0.7x Rel. Volume

In the Jul 8 session, URGN gained 0.74%, reflecting a mild positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

FDA clearance of the IND for UGN-501 opens a Phase 1 intravesical study in NMIBC, adding another bla...

Analysis

FDA clearance of the IND for UGN-501 opens a Phase 1 intravesical study in NMIBC, adding another bladder cancer asset alongside prior UGN-102 milestones. Investors may weigh long development timelines against elevated short interest and recent insider net selling.

Key Figures

Trial phase: Phase 1 Study start timing: Q4 2026 Administration route: Intravesical

3 metrics

Trial phase Phase 1 Planned clinical study for UGN-501 in NMIBC

Study start timing Q4 2026 Expected initiation of Phase 1 UGN-501 trial

Administration route Intravesical Local bladder administration of UGN-501 in Phase 1 study

Previous Clinical trial,fda approval Reports

2 past events · Latest: Dec 05 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 05	Clinical/FDA update	Positive	-2.0%	Promising Phase 3 ENVISION durability data and clear regulatory path for UGN-102.
Oct 15	NDA acceptance	Positive	+2.8%	FDA acceptance of UGN-102 NDA with defined PDUFA timeline for LG-IR-NMIBC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Same-tag clinical/FDA milestones have triggered modest, mixed single-day share reactions for URGN.

Key Terms

investigational new drug application, oncolytic virus, intravesical administration, non-muscle invasive bladder cancer, +1 more

5 terms

investigational new drug application regulatory

"FDA cleared the Company's Investigational New Drug application (IND) for UGN-501"

An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.

oncolytic virus medical

"UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy"

A virus engineered or selected to infect and destroy cancer cells while leaving healthy tissue largely unharmed, often acting like a guided missile that also alerts the immune system to attack tumors. It matters to investors because oncolytic viruses represent a potential new class of cancer treatments that can command large markets if proven safe and effective, but development is costly and outcome-driven, carrying high regulatory and clinical risk.

intravesical administration medical

"evaluate the safety, tolerability, and feasibility of intravesical administration of UGN-501"

A medical delivery method where a liquid drug or therapy is placed directly into the urinary bladder through a thin tube (catheter) rather than taken by mouth or injected into the bloodstream. For investors, this matters because the route of administration affects how well a treatment works, the types of side effects, manufacturing and packaging needs, regulatory hurdles, and the clinical trial design—similar to putting paint directly on a wall instead of spraying the whole room.

non-muscle invasive bladder cancer medical

"Phase 1 clinical study in patients with non-muscle invasive bladder cancer (NMIBC)"

A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.

phase 1 medical

"planned Phase 1 clinical study evaluating local intravesical administration of UGN-501"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026
• UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation

PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug application (IND) for UGN-501, a next-generation investigational oncolytic virus. The IND clearance enables initiation of a planned Phase 1 clinical study in patients with non-muscle invasive bladder cancer (NMIBC). The Phase 1 study is expected to begin in Q4 2026 and will evaluate the safety, tolerability, and feasibility of intravesical administration of UGN-501.

"Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options," said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. "UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of the IND allows us to begin evaluating whether the encouraging nonclinical profile of UGN-501 can translate into a safe and meaningful therapeutic approach for patients with NMIBC. We look forward to initiating the Phase 1 study and advancing our efforts to develop innovative treatment options for patients with bladder cancer."

NMIBC continues to present significant clinical challenges, particularly among patients whose disease recurs following standard treatment. Despite available therapies, recurrence rates remain substantial, underscoring the need for novel bladder-sparing therapeutic approaches. UroGen believes UGN-501's differentiated mechanism of action and local administration strategy may offer a promising new approach for addressing this unmet need.

About UGN-501

UGN-501 is an investigational, next-generation oncolytic virus being investigated for the treatment of non-muscle invasive bladder cancer (NMIBC). UGN-501 is designed to selectively replicate within tumor cells, resulting in direct tumor cell destruction and an anti-tumor immune response. The program is supported by nonclinical data demonstrating cytotoxic activity across a broad panel of bladder cancer cell lines representing multiple stages and grades of disease. While UGN-501 is initially being developed for bladder cancer, the Company believes UGN-501's underlying properties may have broader applicability across additional solid tumor indications and intends to evaluate future development opportunities based on emerging clinical and translational data.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product to treat adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Visit www.UroGen.com to learn more or follow us on X (formerly Twitter), @UroGenPharma.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the planned Phase 1 clinical study of UGN-501 in NMIBC and the expected timing for patient enrollment; the potential benefits of UGN-501, including to selectively target cancer cells while retaining potency, triggering an immune response, and minimizing systemic exposure; UGN-501’s potential as a safe and meaningful therapeutic approach for patients with NMIBC and its potential for broader applicability across additional solid tumor indications; UroGen’s plans to evaluate future development opportunities for NMIBC based on emerging clinical and translational data; the belief that UGN-501 has several attributes that differentiate it from other oncolytic viruses; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “believe,” “can,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: prior results may not be indicative of results that may be observed in the future; the ability to maintain regulatory approval; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology may not perform as expected; UroGen’s financial condition and need for additional capital; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 6, 2026 (which is available at www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083

FAQ

What did UroGen (URGN) announce about FDA clearance for UGN-501 on July 8, 2026?

UroGen announced FDA clearance of the IND for UGN-501, enabling a planned Phase 1 trial in non-muscle invasive bladder cancer. According to UroGen, this will allow first-in-human evaluation of the investigational oncolytic virus via local intravesical administration.

When will UroGen (URGN) begin the Phase 1 clinical trial of UGN-501 for NMIBC?

UroGen expects to begin patient enrollment for the Phase 1 UGN-501 trial in Q4 2026. According to UroGen, the study will assess safety, tolerability, and feasibility of intravesical administration in patients with non-muscle invasive bladder cancer.

What is UGN-501 and how is it designed to work in non-muscle invasive bladder cancer?

UGN-501 is an investigational next-generation oncolytic virus designed for local intravesical delivery in NMIBC. According to UroGen, it aims to selectively destroy tumor cells while also generating an anti-tumor immune response, potentially offering a novel bladder-sparing approach.

What will the Phase 1 UGN-501 trial evaluate for UroGen (URGN) investors to watch?

The Phase 1 trial will evaluate the safety, tolerability, and feasibility of intravesical UGN-501. According to UroGen, this early-stage study in NMIBC patients is a first step to see if encouraging nonclinical data can translate into a viable therapeutic option.

Why does UroGen (URGN) see UGN-501 as important for non-muscle invasive bladder cancer treatment?

UroGen highlights that NMIBC has high recurrence rates despite existing therapies, creating a significant unmet need. According to UroGen, UGN-501’s differentiated mechanism and local administration strategy may offer a promising new bladder-sparing treatment approach if clinical studies are successful.

How does FDA IND clearance of UGN-501 affect UroGen’s bladder cancer pipeline?

FDA IND clearance allows UroGen to start clinical testing of UGN-501 in NMIBC. According to UroGen, initiating a Phase 1 trial advances its efforts to develop innovative bladder cancer treatments and expands its pipeline of urothelial and specialty cancer therapies.